drugset / Trial / NCT07130032
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
Phase 2
Recruiting
90 enrolled
EuroCityClinic LLC
First Pavlov State Medical University in St. Petersburg, Russia · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.
Timeline
- Start
- 2025-08-14
- Primary completion
- 2025-08-14
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |